Cargando…

Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?

Agents targeting vascular endothelial growth factor (VEGF) represent active drugs in treating patients with advanced renal cell carcinoma (RCC). Studies have shown that sunitinib and axitinib can be associated with cardiac toxicity. Whether these agents should be restarted in patients who experience...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Bo, Wood, Laura S., James, Karen, Rini, Brian I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621341/ https://www.ncbi.nlm.nih.gov/pubmed/26550505 http://dx.doi.org/10.1155/2015/817578

Ejemplares similares

Commentary: Antivascular endothelial growth factor and retinopathy of prematurity
por: Dudani, Ajay Indur, et al.
Publicado: (2019)

Use of antivascular endothelial growth factor for diabetic macular edema
por: Karim, Rushmia, et al.
Publicado: (2010)

Restarting exercise safely
Publicado: (2021)

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11
por: Wildiers, H, et al.
Publicado: (2003)

Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor
por: Sassa, Yukio, et al.
Publicado: (2010)

The Use of Antivascular Endothelial Growth Factor Agents in the Perioperative Period in Diabetic Vitrectomy
por: Abu-Yaghi, Nakhleh E., et al.
Publicado: (2012)

Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
por: Zampros, Ilias, et al.
Publicado: (2012)

Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration
por: Tranos, Paris, et al.
Publicado: (2013)

Promising Novel Treatment against Keloids: Antivascular Endothelial Growth Factor Agents
por: Abtahi-Naeini, Bahareh, et al.
Publicado: (2019)

A Clear Cell Renal Cell Carcinoma Inhibiting the Response to Intravitreal Antivascular Endothelial Growth Factor Therapy in Wet Age-Related Macular Disease
por: Falcão, Manuel S., et al.
Publicado: (2012)

Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response
por: Dubrowinskaja, Natalia, et al.
Publicado: (2014)

Antivascular endothelial growth factor‐A therapy: a novel personalized treatment approach for psoriasis
por: Luengas‐Martinez, Andrea, et al.
Publicado: (2022)

Photodynamic therapy combined with antivascular endothelial growth factor treatment for recalcitrant chronic central serous chorioretinopathy
por: Asahi, Masumi G, et al.
Publicado: (2017)

Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration
por: Chandra, Shruti, et al.
Publicado: (2020)

Zinc-Substituted Pheophorbide A Is a Safe and Efficient Antivascular Photodynamic Agent
por: Szafraniec, Milena J., et al.
Publicado: (2022)

Microbubble-enhanced ultrasound for the antivascular treatment and monitoring of hepatocellular carcinoma
por: D'Souza, Julia C., et al.
Publicado: (2019)

The Effect of Antivascular Endothelial Growth Factor on the Development of Adhesion Formation in Laparotomized Rats: Experimental Study
por: Basbug, Murat, et al.
Publicado: (2011)

Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma
por: Mansour, Ahmad M., et al.
Publicado: (2014)

Clinical characteristics and antivascular endothelial growth factor effect of choroidal neovascularization in younger patients in Taiwan
por: Li, Yi-Hsuan, et al.
Publicado: (2015)

Commentary: Ziv-aflibercept: An alternative antivascular endothelial growth factor agent for polypoidal choroidal vasculopathy
por: Anshuman, Kumar, et al.
Publicado: (2019)

Treatment for Nontype 1 Retinopathy of Prematurity by Intravitreal Injection of Antivascular Endothelial Growth Factor Drugs
por: Zhang, Haitao, et al.
Publicado: (2022)

Bilateral choroidal neovascularization associated with optic nerve head drusen treated by antivascular endothelial growth factor therapy
por: Delas, Barbara, et al.
Publicado: (2012)

Antivascular Therapy for Epithelial Ovarian Cancer
por: Duhoux, Francois P., et al.
Publicado: (2010)

Combined argon laser photocoagulation and antivascular endothelial growth factor for management of macular polypoidal choroidal vasculopathy
por: Sen, Parveen, et al.
Publicado: (2016)

Quantitative physiological measurements to evaluate the response of antivascular endothelial growth factor treatment in patients with neovascular diseases
por: Hong, In Hwan, et al.
Publicado: (2017)

Systematic review with network meta-analysis of antivascular endothelial growth factor use in managing polypoidal choroidal vasculopathy
por: Chi, Sheng-Chu, et al.
Publicado: (2021)

Incidence of Acute Endophthalmitis after Intravitreal Antivascular Endothelial Growth Factor Injection in Age-related Macular Degeneration
por: Seong, Hyo Jin, et al.
Publicado: (2022)

Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012)

Risk of Thromboembolic Events and Major Adverse Cardiovascular Events Following Antivascular Endothelial Growth Factor Therapy in Patients with Colorectal Cancer
por: Chen, Yen-Cheng, et al.
Publicado: (2022)

Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma
por: Schwandt, Anita, et al.
Publicado: (2009)

Daily Optical Coherence Tomography Examinations after First Antivascular Endothelial Growth Factor Injections: An Interventional Case Series
por: Novais, Eduardo A., et al.
Publicado: (2016)

Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer
por: Zhang, Ying, et al.
Publicado: (2019)

ASSOCIATION BETWEEN ANATOMICAL AND CLINICAL OUTCOMES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR
por: Nguyen, Vuong, et al.
Publicado: (2021)

Choroidal Vascularity Index as a Biomarker for Visual Response to Antivascular Endothelial Growth Factor Treatment in Diabetic Macular Edema
por: Dou, Ningxin, et al.
Publicado: (2021)

Antivascular Endothelial Growth Factor Dosing Frequency and Visual Outcomes in Macular Edema Following Central Retinal Vein Occlusion
por: Modi, Yasha S., et al.
Publicado: (2021)

Antivascular endothelial growth factor for macular oedema secondary to retinal vein occlusion: a systematic review and meta-analysis
por: Xu, Shanshan, et al.
Publicado: (2022)

The Effect of Antivascular Endothelial Growth Factor Therapy on the Development of Neovascular Glaucoma after Central Retinal Vein Occlusion: A Retrospective Analysis
por: Ryu, Christina L., et al.
Publicado: (2014)

Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy
por: Yang, Jingyuan, et al.
Publicado: (2019)

Nanomaterial-Based Antivascular Therapy in the Multimodal Treatment of Cancer
por: Ma, Xiaocong, et al.
Publicado: (2023)

Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice
por: Sato, Shinri, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fjvpb2v1ko5dqr69tu998qi4b6